Riligustilide is a bioactive compound primarily recognized for its pharmacological potential in traditional medicine, especially in formulations derived from Chinese herbal sources like Ligusticum chuanxiong. It exhibits notable anti-inflammatory and neuroprotective properties, making it a subject of interest in the development of treatments for cerebrovascular and neurodegenerative conditions. Studies suggest it may help reduce cerebral ischemia-reperfusion injury by modulating oxidative stress and inflammatory pathways. It also shows spasmolytic effects on smooth muscle, which can contribute to its use in relieving vascular constriction and improving blood circulation. Additionally, riligustilide has demonstrated anti-cancer activity in preliminary in vitro studies, where it induced apoptosis in certain tumor cell lines, indicating potential as an adjunct in oncology research. Its ability to cross the blood-brain barrier enhances its suitability for central nervous system-targeted therapies.